Search
forLearn
5 / 801 resultslearn oleanolic acid
learn panthenyl ethyl ether
learn Pantothenyl ethylether
learn apple polyphenol
Research
5 / 1000+ resultsresearch Design and Evaluation of Paeonol-Loaded Liposomes in Thermoreversible Gels for Atopic Dermatitis
Paeonol-loaded gels may help reduce inflammation and skin damage in atopic dermatitis.
research In Vivo and In Silico Evaluation of Petroselinum crispum Leaf Fractions as Anti-Alopecia
Parsley leaf fractions may help treat and prevent hair loss.
research Cytoprotective effects of paeoniflorin are associated with translocator protein 18 kDa
Paeoniflorin protects brain cells by involving a specific protein and neurosteroids.
research Palmitoylethanolamide-Incorporated Elastic Nano-Liposomes for Enhanced Transdermal Delivery and Anti-Inflammation
PEA-ENL improves skin delivery and reduces inflammation without side effects.
research Therapeutic potential and pharmacological insights of total glucosides of paeony in dermatologic diseases: a comprehensive review
Total glucosides of paeony can help treat skin conditions but need more research for clinical use.
Community Join
5 / 1000+ resultscommunity Pelage have presented only phase 2a. The rest of phase 2 for PP405 will be presented at a later medical meeting
PP405's phase 2a trial results were presented, focusing on safety and pharmacokinetics, with a future meeting planned to share the full dataset. The trial includes a randomized controlled portion and an open-label extension, with no indication of phase 2B completion.
community Pelage Pharmaceutical Raises 120 million to continue PP405 Research. Link inside.
Pelage Pharmaceutical raised $120 million to continue research on PP405, a promising hair loss treatment that showed a 20% increase in hair density in 31% of men during a Phase 2a trial. The treatment was well-tolerated, with no systemic absorption, and Phase 3 trials are planned for 2026.
community P-1075: a BETTER version of Minoxidil
P-1075 is a more potent hair growth agent than Minoxidil, but it poses significant heart risks, making it unsafe for use. Despite promising results in macaques, concerns about its cardiotoxicity in rats have halted its development.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.